Item 8.01. Other Events.

On October 18, 2021, United Therapeutics Corporation issued a press release announcing that the U.S. Food and Drug Administration issued a complete response for the company's new drug application for Tyvaso DPI™ (inhaled treprostinil). The press release is attached as Exhibit 99.1 and is incorporated herein by reference.

TYVASO DPI is a trademark of United Therapeutics Corporation.





Item 9.01. Exhibits



(d)  Exhibits

Exhibit No.                          Description of Exhibit

  99.1          Press release dated October 18, 2021
104           The cover page from this Current Report on Form 8-K, formatted in
              Inline XBRL




  2

© Edgar Online, source Glimpses